Submit Articles

Global Alzheimer’s Drugs Market Analysis

According to the study done by Ingenious E-Brain Global Alzheimer’s Drug Market is expected to increase at 8.42 % CAGR in the forecast timeline from 2021-2027.

The growing cases of geriatric population prone to Alzheimer, the surging prevalence of chronic diseases, growing government healthcare expenditure for boosting research and development activities, and the rapidly increasing number of drugs in the pipeline stage that could be approved during the forecast timeline are all factors driving the Alzheimer drugs market upward.

Furthermore, increasing healthcare and IT integration, as well as the increasing availability of various business policies, collaborative partnerships, and alliances among key players to facilitate Alzheimer’s drug development, are some of the factors contributing to the growth Alzheimer’s Drugs Market over the forecast timeline.

The report on the Global Alzheimer’s Drug Market provides a comprehensive analysis of the industry. The research includes a detailed analysis of major segments, trends, drivers, constraints, the competitive landscape, revenue possibilities, modifications in market rules, product approvals, strategic choices, product releases, geographical developments, technical developments and other important market variables.

The Alzheimer’s medications market is relatively competitive, with both domestic and international firms.

Key players have been spending in new product development, partnerships, and strategic alliances such as mergers and acquisitions in order to improve their market position.

Some of the key developments in the market are:

  • February 2020 – Biogen Inc. and Sangamo Therapeutics, Inc. have agreed to collaborate on the development and commercialization of ST-501 for tauopathies such as Alzheimer’s disease.
  • June 2021 – The US Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s disease.
  • June 2021 – For the treatment of Alzheimer’s disease, Lilly’s donanemab obtained FDA Breakthrough Therapy Designation.

The Global Alzheimer’s Drug Market is segmented by drug classes (Cholinergic, Memantine, Combination drugs and others), distribution channels (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and geography (North America, Latin America, Europe, APAC, Middle East and Africa).

More info @

Article USA
Shopping cart